NovoCure
NovoCure Ltd is an oncology medical technology company developing Tumor Treating Fields, an electric-field-based cancer therapy. The company designs, manufactures, and markets Optune systems that utilize tuned electric fields to disrupt cancer cell division in glioblastoma and malignant pleural mesothelioma. Main revenue drivers consist of monthly equipment prescription rentals and treatment kit deliveries billed to health insurers and patients. NovoCure serves neuro-oncologists, radiation oncologists, cancer treatment centers, and oncology patients across the United States, Europe, Japan, and Greater China. The company holds a unique pioneer position as the sole commercial developer of electric field cancer therapies globally. Headquartered in St. Helier, Jersey, NovoCure Ltd is listed on the Nasdaq Stock Market.
5 of the funds FundTelligence covers report a position in NovoCure.
- Legal name
- NovoCure Ltd
- Sector
- Health Care
- Country
- Jersey
- Funds holding it
- 5
Funds holding NovoCure
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.14 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- Mercer Global Small Cap Equity Fund — Mercer · 0.09 % (full portfolio disclosed, December 2025)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)